
Ai Ma Biology develops small RNA-based nucleic acid therapeutics to translate biosynthesis research into drug candidates. The company designs and develops small RNA drugs using nucleic acid chemistry and biosynthetic techniques, covering sequence design, synthesis, and preclinical validation. It operates as a biotechnology/biopharma developer serving pharmaceutical companies and research organizations. Ai Ma Biology's platform targets disease-modifying therapeutics derived from biosynthesis advances and supports collaborations for preclinical development.

Ai Ma Biology develops small RNA-based nucleic acid therapeutics to translate biosynthesis research into drug candidates. The company designs and develops small RNA drugs using nucleic acid chemistry and biosynthetic techniques, covering sequence design, synthesis, and preclinical validation. It operates as a biotechnology/biopharma developer serving pharmaceutical companies and research organizations. Ai Ma Biology's platform targets disease-modifying therapeutics derived from biosynthesis advances and supports collaborations for preclinical development.